NRx Pharmaceuticals announced that its Investigational new drug application, or IND, for the use of NRX-101, the company’s patented combination of D-cycloserine and lurasidone, for the treatment of complicated Urinary Tract infections, or cUTI, received clearance from the FDA.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NRXP:
